Critical Analysis: BioNexus Gene Lab (NASDAQ:BGLC) versus Pacific Health Care Organization (OTCMKTS:PFHO)

Pacific Health Care Organization (OTCMKTS:PFHO) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Pacific Health Care Organization and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacific Health Care Organization	20.16%	9.95%	9.58%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 61.6% of Pacific Health Care Organization shares are held by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Pacific Health Care Organization and BioNexus Gene Lab”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Health Care Organization	$6.72 million	1.58	$1.39 million	$0.11	7.55
BioNexus Gene Lab	$7.43 million	0.49	-$2.98 million	($1.48)	-1.02

Pacific Health Care Organization has higher earnings, but lower revenue than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Pacific Health Care Organization, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pacific Health Care Organization has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.08, suggesting that its share price is 308% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Pacific Health Care Organization and BioNexus Gene Lab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Health Care Organization	0	0	0	0	0.00
BioNexus Gene Lab	1	0	0	0	1.00

Summary

Pacific Health Care Organization beats BioNexus Gene Lab on 8 of the 12 factors compared between the two stocks.

About Pacific Health Care Organization

Pacific Health Care Organization, Inc., together with its subsidiaries, operates as a specialty workers' compensation cost containment company in the United States. It is involved in managing and administering health care organizations (HCOs) and medical provider networks (MPNs). The company also provides claims-related services, including utilization review, medical case management, medical bill review, employee advocate services, workers' compensation carve-outs, expert witness testimony, and Medicare set-aside services. It serves insurers, third party administrators, self-administered employers, municipalities, and other industries. The company was formerly known as Clear Air, Inc. and changed its name to Pacific Health Care Organization, Inc. in January 2001. Pacific Health Care Organization, Inc. was incorporated in 1970 and is based in Irvine, California.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.